Key statistics
Previous close$2.75
Open$2.72
Day high$2.80
Day low$2.72
52-week high$3.43
52-week low$1.93
Market cap1.04B
Volume738.53K
Average volume1.51M
P/E ratio-112.96
Forward P/E—
EPS-0.02
Dividend yield0.00%
Market context
Why it moved
Cronos Group (CRON) edged higher amid renewed investor interest, supported by its strong cash position, no debt, improving profitability, and an ongoing share buyback program highlighted in recent coverage of the cannabis company's fundamentals.
What is happening
Recent company-specific developments and publisher coverage.
July 17, 2026Cronos Group closed essentially flat, edging up slightly, as the company announced its Q2 2026 earnings conference call scheduled for August 6 — an event investors will watch closely following a strong Q1 where net income more than doubled year-over-year and revenue surged 40% to $45.2M. The company also recently appointed ATB Cormark as its broker for share repurchases in Canada, signaling continued commitment to returning capital to shareholders. Cronos remains a closely followed name among cannabis peers, with its cash-rich, debt-free balance sheet and growing international presence in Canada, Israel, and Germany underpinning investor interest.0.365
July 16, 2026Cronos Group closed essentially flat as investor focus centers on the company's ongoing share repurchase program and its appeal as a financially sound cannabis stock. The appointment of ATB Cormark as its Canadian buyback broker drew attention this week, underscoring management's commitment to returning capital to shareholders. Analysts continue to highlight Cronos's debt-free balance sheet, $159.5M in revenue, and early profitability — with Q1 2026 net income of $13.8M — as differentiators in a challenged cannabis sector.-0.3636
July 15, 2026Cronos Group closed essentially flat but edged higher in after-hours trading amid renewed analyst attention on its cash-rich, debt-free balance sheet and early profitability. Recent coverage highlighted the company's Q1 2026 results — $59M in revenue and $13.8M in net income — alongside an active buyback that has retired over 10.7 million shares, while its Spinach brand holds a 10.4% share of the Canadian vape market. Broader healthcare sector headwinds, including a projected 9% Q2 earnings drop for XLV constituents, provided little tailwind, though cannabis peers were also featured on watchlists amid sector rotation.July 10, 2026Cronos Group edged higher, supported by renewed investor attention on cannabis names with strong balance sheets. Recent coverage highlighted the company's ~$834 million cash position, zero debt, and Spinach vapes holding a 10.4% share of the Canadian vape market, with the brand cited as the top-selling vape in Canada. MarketBeat flagged CRON among seven cannabis stocks to watch today based on elevated trading volume, while the broader healthcare sector continued to benefit from recent momentum, with XLV having gained 6.6% in June.1.0909
July 9, 2026Cronos Group closed essentially flat amid a broad risk-off session triggered by geopolitical escalation after President Trump signaled the Iran ceasefire deal was "over," sending oil prices sharply higher and weighing on global equities. Despite the macro headwinds, investor attention has remained on Cronos's European expansion narrative — the company recently extended its CanAdelaar acquisition timeline to complete Dutch regulatory approvals — while multiple analyses highlighted its ~$834M cash position, zero debt, and Spinach's 10.4% share of the Canadian vape market as underappreciated strengths. In after-hours trading, shares edged up 1.09% to $2.78.July 8, 2026Cronos Group closed essentially flat as investors weigh the company's ongoing European expansion efforts, highlighted by an extended timeline for its CanAdelaar acquisition in the Netherlands pending regulatory approvals. Analysts continue to focus on the company's notable balance sheet — reportedly holding ~$834 million in cash with no debt — alongside its top-selling Spinach vape brand in Canada, even as the broader cannabis sector faces persistent regulatory uncertainty. The stock underperformed the broader healthcare sector, which posted a second consecutive week of market-leading gains, as Cronos works toward sustained profitability despite trading at a premium P/S multiple.-0.3623
July 7, 2026Cronos Group shares closed modestly lower, giving back ground despite a broadly supportive healthcare sector backdrop and the company's notably strong balance sheet. The stock has attracted attention recently for its ~US$834 million cash position with no debt — a striking reserve relative to its ~CA$1.49 billion market cap — alongside Q1 2026 net income of US$13.75 million and an active share buyback program. Adding to the international growth narrative, Cronos is progressing its CanAdelaar acquisition and expanding medical cannabis operations globally, though cannabis sector volatility and regulatory dependence in Canada and Israel remain key investor concerns.-3.4965
July 1, 2026Cronos Group closed modestly lower as two notable corporate actions grabbed investor attention: the company appointed ATB Cormark as its new Canadian broker for share repurchases under its $50 million buyback program, replacing Virtu Canada, and filed a Form 3 registering new director Darren Chester Broughton as a reporting insider. Underlying investor interest remains anchored to the company's strong fundamentals — ~$834 million in cash, zero debt, Q1 2026 revenue of $45.2 million (up ~40% YoY), and the Spinach brand's leadership in Canadian vapes — alongside the pending CanAdelaar acquisition targeting European medical markets.-2.4561
Ad Hoc News · July 17, 2026Cronos Group stock trades steady as cannabis earnings and cash position shape outlook↗Stock Titan · July 16, 2026Cronos Group management to discuss Q2 results on Aug. 6↗GlobeNewswire · June 30, 2026Cronos Announces Appointment of ATB Cormark as its Broker for Share Repurchases in Canada↗Stock Titan · June 22, 2026Cronos Group shareholders back board, pay vote and auditor↗Stock Titan · June 16, 2026Cannabis firm Cronos plans up to $50M stock buyback in Canada and US↗Seeking Alpha · May 15, 2026Cronos: Strong Q1 Earnings Driven By International Cannabis Sales↗24/7 Wall St. · December 9, 2025Cronos Just Bought Europe’s Top Cannabis Producer - Is This the Catalyst Investors Have Waited 5 Years For?↗ Mt Newswire · June 16, 2026Cronos Extends Share Repurchase Program to Toronto Stock ExchangeMt Newswire · June 16, 2026Cronos Extends a Share Repurchase Program to the Toronto Stock ExchangeMt Newswire · June 16, 2026Under the TSX NCIB, Cronos May Purchase up to 53,968 of its Common Shares on the TSX During Any Trading DayMt Newswire · June 16, 2026Cronos Announcing Extension of Share Repurchase Program to the Toronto Stock ExchangeBenzinga · May 12, 2026TD Cowen Maintains Buy on Cronos Group, Raises Price Target to C$5.5Mt Newswire · May 11, 2026Cronos Up More Than 8% As Q1 Net Income More Than Doubles, Beats ForecastsBenzinga · May 11, 2026Cronos Announces $50M Buyback PlanMt Newswire · May 11, 2026Cronos Group Q1 Net Income, Revenue Rise
